Eosinophils may help identify people with bronchiectasis who benefit more from inhaled steroids, but the evidence is limited. A 2026 review in *Current Opinion in Pulmonary Medicine* explored this link. Bronchiectasis is a lung condition where airways become damaged and widened. The review examined existing evidence, rather than testing a new treatment. It focused on eosinophils, immune cells that can contribute to airway swelling. For members tracking Eosinophils %, the key takeaway is that context matters. This measure shows the share of your white blood cells that are eosinophils. The review discussed raised eosinophils in blood or mucus from the lungs. It did not establish a percentage cutoff for choosing treatment. Some people with bronchiectasis have airway swelling linked to these cells. Higher blood counts may point to greater benefit from inhaled steroids. These are medicines breathed into the lungs to reduce swelling. Early findings also look promising for biologics, medicines targeting specific immune signals. But most treatment evidence comes from observing care, not controlled treatment tests. The picture is harder to untangle when asthma or allergic lung disease overlaps. Benefits from biologics are especially uncertain in people without those conditions. There is no agreed best test or cutoff yet. The supplied summary gives no study sizes or numbers showing treatment benefit. For this community, that makes the result a clue, not a treatment rule. Keeping bloodwork dates alongside breathing symptoms and treatment changes can add context. Comparing notes with members who have similar lung conditions may be more useful than comparing percentages alone. What patterns have you noticed between your Eosinophils % results, breathing symptoms, and treatment changes?